ES3044311T3 - Method of safely and effectively treating and preventing secondary hyperparathyroidism in chronic kidney disease - Google Patents

Method of safely and effectively treating and preventing secondary hyperparathyroidism in chronic kidney disease

Info

Publication number
ES3044311T3
ES3044311T3 ES17158264T ES17158264T ES3044311T3 ES 3044311 T3 ES3044311 T3 ES 3044311T3 ES 17158264 T ES17158264 T ES 17158264T ES 17158264 T ES17158264 T ES 17158264T ES 3044311 T3 ES3044311 T3 ES 3044311T3
Authority
ES
Spain
Prior art keywords
hydroxyvitamin
patient
stage
vitamin
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES17158264T
Other languages
English (en)
Spanish (es)
Inventor
Charles Bishop
Eric Messner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Opko Renal LLC
Original Assignee
Opko Renal LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Opko Renal LLC filed Critical Opko Renal LLC
Application granted granted Critical
Publication of ES3044311T3 publication Critical patent/ES3044311T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/592—9,10-Secoergostane derivatives, e.g. ergocalciferol, i.e. vitamin D2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Nutrition Science (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
ES17158264T 2007-04-25 2008-04-25 Method of safely and effectively treating and preventing secondary hyperparathyroidism in chronic kidney disease Active ES3044311T3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US91385007P 2007-04-25 2007-04-25

Publications (1)

Publication Number Publication Date
ES3044311T3 true ES3044311T3 (en) 2025-11-26

Family

ID=39926088

Family Applications (2)

Application Number Title Priority Date Filing Date
ES18155042T Active ES3047207T3 (en) 2007-04-25 2008-04-25 Method of safely and effectively treating and preventing secondary hyperparathyroidism in chronic kidney disease
ES17158264T Active ES3044311T3 (en) 2007-04-25 2008-04-25 Method of safely and effectively treating and preventing secondary hyperparathyroidism in chronic kidney disease

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES18155042T Active ES3047207T3 (en) 2007-04-25 2008-04-25 Method of safely and effectively treating and preventing secondary hyperparathyroidism in chronic kidney disease

Country Status (10)

Country Link
US (3) US20100144684A1 (OSRAM)
EP (3) EP3225243B1 (OSRAM)
JP (5) JP2010525080A (OSRAM)
CA (1) CA2683514C (OSRAM)
DK (2) DK3225243T3 (OSRAM)
ES (2) ES3047207T3 (OSRAM)
FI (2) FI3335712T3 (OSRAM)
PT (2) PT3225243T (OSRAM)
SI (1) SI3225243T1 (OSRAM)
WO (1) WO2008134523A1 (OSRAM)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8404667B2 (en) * 2006-12-29 2013-03-26 Wisconsin Alumni Research Foundation Compounds, compositions, kits and methods of use to orally and topically treat acne and other skin conditions by 19-Nor vitamin D analog
SI1993559T1 (sl) 2006-02-03 2017-01-31 Opko Renal, Llc Zdravljenje nezadostnosti in pomanjkanja vitamina D s 25-hidroksivitaminon D2 in 25-hidroksivitaminom D3
PT2679228T (pt) 2006-06-21 2018-04-16 Opko Ireland Global Holdings Ltd Terapia utilizando um agente de repleção de vitamina d e um agente de substituição hormonal de vitamina d
CN104257667B (zh) 2007-04-25 2019-06-04 欧普科Ip 控股Ii 有限公司 治疗维生素d不足和缺乏、继发性甲状旁腺功能亢进症和维生素d-响应疾病的方法和组合物
EP3225243B1 (en) 2007-04-25 2025-09-03 Opko Renal, LLC Method of safely and effectively treating and preventing secondary hyperparathyroidism in chronic kidney disease
CA2684778C (en) 2007-04-25 2017-09-05 Cytochroma Inc. Methods and compounds for vitamin d therapy
KR101959952B1 (ko) 2007-04-25 2019-03-19 사이토크로마 인코포레이티드 비타민 ｄ 화합물과 밀랍성 담체를 포함하는 경구 조절성 방출 조성물
EP2240183A1 (en) * 2008-02-13 2010-10-20 DSM IP Assets B.V. Combination of vitamin d and 25-hydroxyvitamin d 3
CN106853250A (zh) 2008-04-02 2017-06-16 赛特克罗公司 用于维生素d缺乏症和相关障碍的方法、组合物、用途和试剂盒
JP5908402B2 (ja) * 2009-08-03 2016-04-26 ウィスコンシン・アルムニ・リサーチ・ファウンデーションＷｉｓｃｏｎｓｉｎ Ａｌｕｍｎｉ Ｒｅｓｅａｒｃｈ Ｆｏｕｎｄａｔｉｏｎ 腎疾患の予防方法およびその症状を処置する方法
US8518917B2 (en) * 2009-10-02 2013-08-27 Wisconsin Alumni Research Foundation 2-methylene-19-nor-vitamin D analogs and their uses
ES2783980T3 (es) 2010-03-29 2020-09-21 Opko Ireland Global Holdings Ltd Métodos y composiciones para la reducción de niveles de paratiroides
US20130252927A1 (en) * 2010-12-06 2013-09-26 Dsm Ip Assets, B.V. Treating conditions associated with increased eotaxin with 25-hydroxyvitamin d3
KR101847947B1 (ko) 2013-03-15 2018-05-28 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 안정화되고 변형된 비타민 ｄ 방출 제형
US20180085381A1 (en) * 2014-08-07 2018-03-29 Opko Ireland Global Holdings, Ltd. Adjunctive Therapy With 25-Hydroxyvitamin D
US10220047B2 (en) 2014-08-07 2019-03-05 Opko Ireland Global Holdings, Ltd. Adjunctive therapy with 25-hydroxyvitamin D and articles therefor
US9539264B2 (en) * 2014-12-30 2017-01-10 Wisconsin Alumni Research Foundation Use of 2-methylene-19-nor-(20S)-1-alpha,25-dihydroxyvitamin D3 to treat secondary hyperparathyroidism in patients previously treated with calcimimetics
CN108370575A (zh) * 2016-01-05 2018-08-03 富士通株式会社 信息传输方法、装置和系统
MY198547A (en) 2016-03-28 2023-09-04 Opko Ireland Global Holdings Ltd Methods of vitamin d treatment
CA3045306A1 (en) 2016-11-29 2018-06-07 Boston Biomedical, Inc. Naphthofuran derivatives, preparation, and methods of use thereof
EP3665705B1 (en) 2017-08-08 2024-12-18 Fresenius Medical Care Holdings, Inc. Systems and methods for treating and estimating progression of chronic kidney disease
JP7590184B2 (ja) 2018-04-03 2024-11-26 オプコ アイルランド グローバル ホールディングス リミテッド 肥満外科手術患者におけるカルシフェジオールの使用
AU2020218639A1 (en) 2019-02-06 2021-08-12 Eirgen Pharma Ltd. Method of controlling progression of hyperparathyroidism with calcifediol, and compositions for use therein
CN115768412A (zh) * 2020-05-31 2023-03-07 艾尔金制药有限公司 硬胶囊剂型和其用途
WO2025094144A1 (en) 2023-11-02 2025-05-08 Eirgen Pharma Ltd. Controlling loss of kidney function

Family Cites Families (170)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3565924A (en) 1968-07-01 1971-02-23 Wisconsin Alumni Res Found 25-hydroxycholfcalciferol
US3833622A (en) 1969-03-17 1974-09-03 Upjohn Co Crystalline 25-hydroxycholecalciferol hydrate and structurally related compounds
US3974272A (en) * 1972-09-01 1976-08-10 Merck & Co., Inc. Palatable cholestyramine coacervate compositions
US3880894A (en) 1974-05-24 1975-04-29 Wisconsin Alumni Res Found 1,25-Dihydroxyergocalciferol
US4004003A (en) 1974-08-28 1977-01-18 The Upjohn Company 25-Hydroxycalciferol compounds for treatment of steroid-induced osteoporosis
US4335120A (en) 1979-03-21 1982-06-15 Hoffmann-La Roche Inc. Administration of biologically active vitamin D3 and vitamin D2 materials
US4230701A (en) 1979-03-21 1980-10-28 Hoffmann-La Roche Inc. Administration of biologically active vitamin D3 and vitamin D2 materials
JPS5832823A (ja) 1981-08-20 1983-02-25 Chugai Pharmaceut Co Ltd 脱癌剤
US4721613A (en) 1982-12-13 1988-01-26 Alza Corporation Delivery system comprising means for shielding a multiplicity of reservoirs in selected environment of use
JPS59155309A (ja) 1983-02-22 1984-09-04 Teijin Ltd 活性型ビタミンｄ↓３類組成物
US4684524A (en) 1984-03-19 1987-08-04 Alza Corporation Rate controlled dispenser for administering beneficial agent
US4555364A (en) 1984-11-01 1985-11-26 Wisconsin Alumni Research Foundation Method for preparing 1-hydroxyvitamin D compounds
US4695591A (en) 1985-03-29 1987-09-22 Schering Corporation Controlled release dosage forms comprising hydroxypropylmethylcellulose
US4668517A (en) 1985-04-04 1987-05-26 Norwich Eaton Pharmaceuticals, Inc. Furazolidone dosage form
EP0207638B1 (en) 1985-06-04 1990-12-19 Teijin Limited Sustained-release pharmaceutical preparation
JPS61293911A (ja) 1985-06-24 1986-12-24 Teisan Seiyaku Kk 徐放化製剤
US5167965A (en) * 1987-02-09 1992-12-01 The Dow Chemical Company Palatable cholestyramine granules, tablets and methods for preparation thereof
US4997824A (en) 1987-07-22 1991-03-05 Teva Pharmaceutical Industries Ltd. Combination of cholecalciferol derivatives for the treatment of renal bone disease
US5869473A (en) 1988-08-02 1999-02-09 Bone Care International, Inc. Method for treating and preventing hyperparathyroidism
US5602116A (en) 1988-08-02 1997-02-11 Bone Care International, Inc. Method for treating and preventing secondary hyperparathyroidism
US5104864A (en) 1988-08-02 1992-04-14 Bone Care International, Inc. Method for treating and preventing loss of bone mass
JP2893191B2 (ja) 1988-11-08 1999-05-17 武田薬品工業株式会社 放出制御性マトリックス剤
JPH02240024A (ja) 1989-03-13 1990-09-25 Ss Pharmaceut Co Ltd 活性型ビタミンｄ↓３類製剤用組成物
US5026559A (en) 1989-04-03 1991-06-25 Kinaform Technology, Inc. Sustained-release pharmaceutical preparation
GB9004544D0 (en) 1990-03-01 1990-04-25 Leo Pharm Prod Ltd Novel treatment ii
JP2845342B2 (ja) 1990-04-28 1999-01-13 大正製薬株式会社 ビタミンｄ▲下３▼誘導体含有固形製剤組成物
JP2893140B2 (ja) 1990-11-30 1999-05-17 エスエス製薬株式会社 安定なビタミンｄ製剤
JPH04288016A (ja) 1991-03-14 1992-10-13 Tokai Capsule Kk 活性型ビタミンｄ３類軟カプセル剤の製造方法
ES2094290T3 (es) 1991-04-09 1997-01-16 Takeda Chemical Industries Ltd Preparacion estabilizada de vitamina d.
US5693615A (en) 1991-06-05 1997-12-02 The Procter & Gamble Company Therapeutic compositions for osteoinduction
US5266331A (en) 1991-11-27 1993-11-30 Euroceltique, S.A. Controlled release oxycodone compositions
US5472712A (en) 1991-12-24 1995-12-05 Euroceltique, S.A. Controlled-release formulations coated with aqueous dispersions of ethylcellulose
US5160742A (en) 1991-12-31 1992-11-03 Abbott Laboratories System for delivering an active substance for sustained release
WO1994000128A1 (en) 1992-06-22 1994-01-06 Lunar Corporation ORAL 1α-HYDROXYPREVITAMIN D
US5795882A (en) 1992-06-22 1998-08-18 Bone Care International, Inc. Method of treating prostatic diseases using delayed and/or sustained release vitamin D formulations
US5354743A (en) 1992-09-15 1994-10-11 Thys Jacobs Susan Method for the treatment of premenstrual syndrome with vitamin D
US5431917A (en) 1992-10-08 1995-07-11 Japan Elanco Company, Ltd. Hard capsule for pharmaceutical drugs and method for producing the same
US5342626A (en) 1993-04-27 1994-08-30 Merck & Co., Inc. Composition and process for gelatin-free soft capsules
JP2684587B2 (ja) 1993-06-21 1997-12-03 呉羽化学工業株式会社 腎性骨異栄養症における骨量減少抑制剤
US6121469A (en) 1993-12-23 2000-09-19 The Regents Of The University Of California Therapeutically effective 1α,25-dihydroxyvitamin D3 analogs
JPH07242550A (ja) * 1994-03-02 1995-09-19 Teijin Ltd 二次性副甲状腺機能亢進症治療剤
IL110117A0 (en) 1994-06-24 1994-10-07 Univ Ben Gurion Pharmaceutical compositions comprising vitamin-d analogs
SE9402422D0 (sv) 1994-07-08 1994-07-08 Astra Ab New beads for controlled release and a pharmaceutical preparation containing the same
JPH10504291A (ja) 1994-07-22 1998-04-28 ジー．ディー．サール アンド カンパニー 自己乳化性ドラッグデリバリーシステム
JPH0892098A (ja) 1994-09-27 1996-04-09 Teijin Ltd 肺結核治療剤
US5756123A (en) 1994-12-01 1998-05-26 Japan Elanco Co., Ltd. Capsule shell
US20020183288A1 (en) * 1995-04-03 2002-12-05 Bone Care International, Inc. Method for treating and preventing hyperparathyroidism
US20040043971A1 (en) * 1995-04-03 2004-03-04 Bone Care International, Inc. Method of treating and preventing hyperparathyroidism with active vitamin D analogs
US6376479B1 (en) 1995-04-03 2002-04-23 Bone Care International, Inc. Method for treating and preventing hyperparathyroidism
US6242434B1 (en) 1997-08-08 2001-06-05 Bone Care International, Inc. 24-hydroxyvitamin D, analogs and uses thereof
EP1021401A1 (en) 1995-09-21 2000-07-26 Wisconsin Alumni Research Foundation Calcitriol derivatives and their uses
DE19549243A1 (de) 1995-12-21 1997-06-26 Schering Ag Pharmazeutische Präparate enthaltend Clathrate von Cyclodextrinen und nichtnatürliche Vitamin D-Analoga
CA2264131A1 (en) * 1996-08-26 1998-03-05 Takeda Chemical Industries, Ltd. Pharmaceutical composition containing osteogenesis-promoting substance
US5958451A (en) 1996-09-03 1999-09-28 Yung Shin Pharm Ind. Co., Ltd. Process for producing porous, controlled-release capsules and encapsulated composition
JP2002511777A (ja) 1996-10-28 2002-04-16 ゼネラル ミルズ，インコーポレイテッド 調放性粒子の埋包およびカプセル化
JPH10158171A (ja) 1996-12-02 1998-06-16 Kita:Kk ビタミンｄ化合物を配合した眼内投与剤
US20020128240A1 (en) 1996-12-30 2002-09-12 Bone Care International, Inc. Treatment of hyperproliferative diseases using active vitamin D analogues
US6503893B2 (en) * 1996-12-30 2003-01-07 Bone Care International, Inc. Method of treating hyperproliferative diseases using active vitamin D analogues
US20030129194A1 (en) 1997-02-13 2003-07-10 Bone Care International, Inc. Targeted therapeutic delivery of vitamin D compounds
US6034075A (en) 1997-03-20 2000-03-07 The Trustees Of Columbia University In The City Of New York Method of treating polycystic ovarian syndrome
JPH1175863A (ja) 1997-07-10 1999-03-23 Kyowa Hakko Kogyo Co Ltd ２５−ヒドロキシビタミンＤ３−１α−水酸化酵素および該酵素をコードするＤＮＡ
AU9376998A (en) 1997-09-02 1999-03-22 Johns Hopkins University School Of Medicine, The Vitamin d3 analog loaded polymer formulations for cancer and neurodegenerative disorders
ES2368824T3 (es) 1998-03-27 2011-11-22 Oregon Health & Science University Vitamina d y sus análogos en el tratamiento de tumores y otros desórdenes hiperproliferativos.
US6197340B1 (en) 1998-05-28 2001-03-06 Medical Research Institute Controlled release lipoic acid
WO2000012069A1 (en) 1998-08-27 2000-03-09 Pharmacia & Upjohn Ab Therapeutic formulation for administering tolterodine with controlled release
SE9803871D0 (sv) 1998-11-11 1998-11-11 Pharmacia & Upjohn Ab Therapeutic method and formulation
US6139875A (en) 1998-09-29 2000-10-31 Eastman Chemical Company Aqueous enteric coating composition and low gastric permeability enteric coating
JP2002525311A (ja) 1998-10-01 2002-08-13 エラン ファーマ インターナショナル，リミティド 徐放性ナノ粒子組成物
AU777977B2 (en) 1998-10-09 2004-11-04 General Mills Inc. Encapsulation of sensitive liquid components into a matrix to obtain discrete shelf-stable particles
JP3449253B2 (ja) 1998-10-29 2003-09-22 シオノギクオリカプス株式会社 硬質カプセルの製造方法
JP2000206312A (ja) * 1998-11-12 2000-07-28 Olympus Optical Co Ltd 光学素子
KR100634069B1 (ko) 1998-12-17 2006-10-16 알자 코포레이션 다중 코팅에 의한, 액체 충진 젤라틴 캡슐로부터 제어방출 시스템으로의 전환
US6342249B1 (en) 1998-12-23 2002-01-29 Alza Corporation Controlled release liquid active agent formulation dosage forms
US6432936B1 (en) 1999-01-20 2002-08-13 Wisconsin Alumni Research Foundation Crystalline 1α-hydroxyvitamin D2 and method of purification thereof
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
DE60031666T2 (de) 1999-04-01 2007-08-30 The Johns Hopkins University NICHT-CALCEMISCHE, TRANSKRIPTIONELL-AKTIVE, SCHWEFELHALTIGE ANALOGA VON 1-alpha, 25-DIHYDROXYVITAMIN D3 MIT ANTIPROLIFERATIVER WIRKUNG
DE19916419B4 (de) 1999-04-08 2005-06-16 Schering Ag Kombinationspräparat aus Vitamin-D-Metaboliten oder Vitamin-D-Analoga und einem Östrogenpartialagonisten zur Behandlung von Osteoporose
AU5139600A (en) * 1999-05-27 2000-12-18 Drugtech Corporation Nutritional formulations
US6340473B1 (en) 1999-07-07 2002-01-22 R.P. Scherer Technologies, Inc. Film forming compositions comprising modified starches and iota-carrageenan and methods for manufacturing soft capsules using same
US6274169B1 (en) 1999-08-02 2001-08-14 Abbott Laboratories Low oxygen content compostions of 1α, 25-dihydroxycholecalciferol
US6051567A (en) 1999-08-02 2000-04-18 Abbott Laboratories Low oxygen content compositions of 1α, 25-dihydroxycholecalciferol
KR100587245B1 (ko) 1999-08-31 2006-06-07 쥬가이 세이야쿠 가부시키가이샤 연질 캡슐제
US20060034937A1 (en) 1999-11-23 2006-02-16 Mahesh Patel Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
GB0007419D0 (en) 2000-03-27 2000-05-17 Smithkline Beecham Gmbh Composition
US6375981B1 (en) 2000-06-01 2002-04-23 A. E. Staley Manufacturing Co. Modified starch as a replacement for gelatin in soft gel films and capsules
AU7895601A (en) 2000-07-18 2002-01-30 Bone Care Int Inc Stabilized 1alpha-hydroxy vitamin d
KR100829474B1 (ko) 2000-08-29 2008-05-16 닛신 가세이 가부시키가이샤 경질 캡슐
US6733783B2 (en) 2000-10-30 2004-05-11 Euro-Celtique S.A. Controlled release hydrocodone formulations
US6479649B1 (en) 2000-12-13 2002-11-12 Fmc Corporation Production of carrageenan and carrageenan products
IL158518A0 (en) * 2001-05-15 2004-05-12 Warner Lambert Co Compaction process for manufacture of sodium phenytoin dosage form
US7846475B2 (en) 2001-07-05 2010-12-07 Wakunaga Pharmaceutical Co., Ltd. Soft capsules
US7033996B2 (en) 2001-08-31 2006-04-25 University Of Medicine & Dentistry Of New Jersey Method for the treatment of vitamin D related disease
DE10149674A1 (de) * 2001-10-09 2003-04-24 Apogepha Arzneimittel Gmbh Orale Darreichungsformen für Propiverin oder seinen pharmazeutisch annehmbaren Salzen mit verlängerter Wirkstoffreisetzung
ES2283593T3 (es) 2001-10-12 2007-11-01 Johns Hopkins University Analogos de oxima poco calcemicos de 1alfa,25-dihidroxi vitamina d3.
US7056655B2 (en) * 2001-11-02 2006-06-06 Scantibodies Laboratory, Inc. Methods for monitoring and guiding therapeutic suppression of parathyroid hormone in renal patients having secondary hyperparathyroidism
US6524788B1 (en) 2001-11-02 2003-02-25 Thomas L. Cantor Methods for monitoring and guiding therapeutic suppression of parathyroid hormone in renal patients having secondary hyperparathyroidism
ITMI20012366A1 (it) 2001-11-09 2003-05-09 Farmatron Ltd Sistemi terapeutici stabilizzati a rilascio immediato e/o modificato per la somministrazione orale di principi attivi e/o eccipienti e/o ali
CN100335133C (zh) 2001-11-22 2007-09-05 森下仁丹株式会社 非胶凝状的胶囊膜组合物和使用其所形成的胶囊
HUP0501186A2 (en) 2001-12-03 2006-05-29 Novacea Pharmaceutical compositions comprising active vitamin d compounds
FR2829142B1 (fr) 2001-12-27 2004-02-13 Ulice Composition filmogene d'heteroxylanes pour la fabrication de capsules ainsi obtenues
US7632518B2 (en) 2002-01-15 2009-12-15 Dsm Ip Assets B.V. 25-hydroxy vitamin D3 compositions
US6949256B2 (en) 2002-01-18 2005-09-27 Banner Pharmacaps, Inc. Non-gelatin capsule shell formulation
NO20021592D0 (no) 2002-04-04 2002-04-04 Fmc Biopolymer As Polysakkaridkapsler og fremgangsmåte ved fremstilling derav
US20050176685A1 (en) * 2002-04-05 2005-08-11 Daifotis Anastasia G. Method for inhibiting bone resorption with an alendronate and vitamin d formulation
AU2003233735A1 (en) 2002-06-13 2003-12-31 Cytochroma Inc. 24-sulfoximine vitamin d3 compounds
US20060127484A1 (en) 2002-07-05 2006-06-15 Speirs Christopher J Controlled release composition
ATE373472T1 (de) * 2002-07-29 2007-10-15 Alza Corp Verfahren und dosierformen für die kontrollierte abgabe von paliperidon
US8268352B2 (en) 2002-08-05 2012-09-18 Torrent Pharmaceuticals Limited Modified release composition for highly soluble drugs
WO2004028515A1 (en) 2002-09-26 2004-04-08 Young-Kweon Choi Matrix type patch for transdermal administration of vitamin d analog and the use thereof
US20050101576A1 (en) 2003-11-06 2005-05-12 Novacea, Inc. Methods of using vitamin D compounds in the treatment of myelodysplastic syndromes
US8999372B2 (en) 2002-11-14 2015-04-07 Cure Pharmaceutical Corporation Methods for modulating dissolution, bioavailability, bioequivalence and drug delivery profile of thin film drug delivery systems, controlled-release thin film dosage formats, and methods for their manufacture and use
JP2004175750A (ja) 2002-11-28 2004-06-24 Kose Corp 皮膚障害抑制剤、皮膚障害改善剤、及びそれらを含有する皮膚外用剤
WO2004058235A2 (en) 2002-12-16 2004-07-15 Teva Pharmaceutical Industries Ltd. Method of increasing bioavailability of alendronate or other bis-phosphonate by predose administration of vitamin d derivative
EP1592410B1 (en) * 2003-02-11 2008-07-23 Alza Corporation Methods and dosage forms with modified layer geometry
US7816341B2 (en) 2003-04-14 2010-10-19 Fmc Corporation Homogeneous, thermoreversible gel containing reduced viscosity carrageenan and products made therefrom
BRPI0409342A (pt) 2003-04-14 2006-04-25 Fmc Corp pelìcula de gel termorreversìvel homogênea, cápsulas moles, processos para fabricar as pelìculas de gel e para fabricar cápsulas moles contendo as pelìculas de gel, e, forma sólida
EP1622455A4 (en) * 2003-04-30 2009-12-16 Bioxell Spa GEMINI VITAMIN D3 COMPOUNDS AND METHODS OF USING THE SAME
EP1479677A1 (en) 2003-05-19 2004-11-24 Aventis Pharma Deutschland GmbH New indole derivatives as factor xa inhibitors
WO2004110391A2 (en) 2003-06-16 2004-12-23 Solx, Inc. Shunt for the treatment of glaucoma
US20050148557A1 (en) 2003-07-29 2005-07-07 Jin Tian Use of Vitamin Ds to treat kidney disease
US20050124591A1 (en) 2003-07-29 2005-06-09 Jin Tian Use of vitamin Ds to treat kidney disease
US20080064668A1 (en) * 2003-09-24 2008-03-13 Bioxell S.P.A. 1,3-Diacylated, 26,27-Alkyl/Haloakyl Vitamin D3 Compounds and Methods of Use Thereof
US7053075B2 (en) 2003-11-25 2006-05-30 Deluca Hector F Methods for reducing body fat using vitamin D compounds
US20060009425A1 (en) 2004-05-28 2006-01-12 Leticia Delgado-Herrera Oral formulations of paricalcitol
WO2005123120A1 (en) 2004-06-16 2005-12-29 Smart Drug Systems Inc. Sustained release vaccine composition
US20050287213A1 (en) 2004-06-28 2005-12-29 Wong Patrick S Dosage forms for low solubility and or low dissolution rate free acid pharmaceutical agents
US20060019933A1 (en) 2004-07-22 2006-01-26 David Boardman Process for preparing stabilized vitamin D
KR20070043806A (ko) 2004-07-29 2007-04-25 사노피-아벤티스 ｐＨ에 매우 의존적인 용해도를 가지는 활성 성분의 제어방출을 위한 약제학적 다층 정제
CA2583548A1 (en) * 2004-10-15 2006-04-27 Altairnano, Inc. Phosphate binder with reduced pill burden
US8231896B2 (en) 2004-11-08 2012-07-31 R.P. Scherer Technologies, Llc Non-gelatin soft capsule system
AU2004325362B2 (en) 2004-12-03 2012-09-06 Council Of Scientific And Industrial Research Process of preparation of biodegradable films from semi refined kappa carrageenan
US8318210B2 (en) 2005-02-28 2012-11-27 Neos Therapeutics, Lp Compositions and methods of making sustained release liquid formulations
US7745226B2 (en) 2005-04-06 2010-06-29 Quest Diagnostics Investments Incorporated Methods for detecting vitamin D metabolites
RU2623206C2 (ru) 2005-04-15 2017-06-22 Кларус Терапьютикс, Инк. Фармацевтические системы доставки для гидрофобных лекарственных средств и композиций, их содержащих
US20060257481A1 (en) 2005-04-21 2006-11-16 Decode Genetics Ehf. Sustained release formulation and dosing schedule of leukotriene synthesis inhibitor for human therapy
US20080134937A1 (en) 2005-05-25 2008-06-12 Joo Hwan Yang Cellulose hard capsule enhancing mechanical film strength
AR055099A1 (es) 2005-07-28 2007-08-08 Alza Corp Formulaciones liquidas para la administracion controlada de derivados de bencisoxazol
ES2323900T3 (es) 2005-09-29 2009-07-27 F. Hoffmann-La Roche Ag Anticuerpos contra la 25-hidroxivitamina d.
ITFI20050206A1 (it) 2005-09-30 2007-04-01 Valpharma Sa Composizione farmaceutica a rilascio controllato di venlafaxina cloridrato, e processo per la sua preparazione
CA2624897C (en) * 2005-10-12 2017-02-14 Proventiv Therapeutics, Llc Methods and articles for treating 25-hydroxyvitamin d insufficiency and deficiency
CN101351196B (zh) 2005-10-26 2013-07-03 班纳制药公司 作为胶囊填充物的基于亲脂性载体的双重控释基质系统
CA2627292C (en) 2005-10-26 2012-04-17 Banner Pharmacaps, Inc. Hydrophilic vehicle-based dual controlled release matrix system
KR20080106160A (ko) 2005-11-01 2008-12-04 씨피 켈코 유에스, 인코포레이티드 변성 카르복시메틸셀룰로오스 물질로 제조된 필름 및 캡슐및 그의 제조방법
WO2007068287A1 (en) 2005-12-15 2007-06-21 Laboratoria Qualiphar Sustained release vitamin preparation
SI1993559T1 (sl) * 2006-02-03 2017-01-31 Opko Renal, Llc Zdravljenje nezadostnosti in pomanjkanja vitamina D s 25-hidroksivitaminon D2 in 25-hidroksivitaminom D3
JP2009540053A (ja) 2006-06-06 2009-11-19 エフ エム シー コーポレーション カッパー−２カラギーナン組成物及びそれからつくられた製品
PT2679228T (pt) * 2006-06-21 2018-04-16 Opko Ireland Global Holdings Ltd Terapia utilizando um agente de repleção de vitamina d e um agente de substituição hormonal de vitamina d
MX2009004434A (es) 2006-10-27 2009-05-08 Pfizer Prod Inc Capsulas duras de hidroxipropilmetilcelulosa y procedimiento de fabricacion.
US8501717B2 (en) 2007-02-09 2013-08-06 Merck, Sharp & Dohme Corp. Methods to treat and/or prevent mucositis
EP3225243B1 (en) 2007-04-25 2025-09-03 Opko Renal, LLC Method of safely and effectively treating and preventing secondary hyperparathyroidism in chronic kidney disease
KR101959952B1 (ko) 2007-04-25 2019-03-19 사이토크로마 인코포레이티드 비타민 ｄ 화합물과 밀랍성 담체를 포함하는 경구 조절성 방출 조성물
CN104257667B (zh) 2007-04-25 2019-06-04 欧普科Ip 控股Ii 有限公司 治疗维生素d不足和缺乏、继发性甲状旁腺功能亢进症和维生素d-响应疾病的方法和组合物
DE102008006203B4 (de) * 2008-01-26 2011-03-17 Jost-Werke Gmbh Fahrzeugkupplung zum Herstellen einer mechanischen Verbindung zwischen einem ersten und einem zweiten Fahrzeug
EP2240183A1 (en) 2008-02-13 2010-10-20 DSM IP Assets B.V. Combination of vitamin d and 25-hydroxyvitamin d 3
WO2009101137A1 (en) 2008-02-13 2009-08-20 Dsm Ip Assets B.V. Use of 25-hydroxy-vitamin d3 to affect human muscle physiology
AU2009273889B2 (en) 2008-07-24 2013-01-31 Wisconsin Alumni Research Foundation Once-a-week administration of 25-hydroxy vitamin D3 to sustain elevated steady-state pharmacokinetic blood concentration
BRPI0823096B8 (pt) 2008-09-24 2022-07-05 Evonik Roehm Gmbh composição farmacêutica de opióide de liberação controlada, dependente do ph, com resistência contra a influência do etanol, processo para sua preparação, e seu uso
WO2011031617A2 (en) 2009-09-10 2011-03-17 Fmc Corporation Seamless alginate capsules
US8101204B2 (en) 2010-01-14 2012-01-24 Karl Wei Cao Hard capsule composition and method of use
US8101203B2 (en) 2010-01-14 2012-01-24 Karl Wei Cao Hard capsule composition and method of use
WO2011095388A1 (en) 2010-02-04 2011-08-11 Synthon Bv Tolterodine bead
CA2807314C (en) 2010-08-04 2017-06-20 R.P. Scherer Technologies, Llc Film-forming composition for soft capsules
US20130252927A1 (en) 2010-12-06 2013-09-26 Dsm Ip Assets, B.V. Treating conditions associated with increased eotaxin with 25-hydroxyvitamin d3
CA2821415C (en) 2010-12-28 2017-08-01 Future Diagnostics B.V. Release reagent for vitamin d
DK2680826T3 (en) 2011-03-02 2017-10-09 D3 Pharma Ltd VITAMIN D COMPOSITION
US8992971B2 (en) 2011-04-20 2015-03-31 Suheung Capsule Co., Ltd. Non-animal soft capsule shell composition having improved disintegration and shell hardness
CN102771688A (zh) 2011-05-13 2012-11-14 富曼实（上海）商贸有限公司 可食用液体填充的多糖胶囊
EP2815745A1 (en) 2013-06-21 2014-12-24 Swiss Caps Rechte und Lizenzen AG Soft shell capsule and process for its manufacture
CN103495176B (zh) 2013-10-26 2015-01-28 中山市凯博思淀粉材料科技有限公司 一种共混挤出法制备淀粉基软胶囊的方法
CN103520133B (zh) 2013-10-26 2015-02-04 中山市凯博思淀粉材料科技有限公司 一种淀粉基软胶囊的制备方法

Also Published As

Publication number Publication date
US20100144684A1 (en) 2010-06-10
PT3225243T (pt) 2025-10-01
EP3335712A1 (en) 2018-06-20
JP2014098034A (ja) 2014-05-29
JP2018009040A (ja) 2018-01-18
ES3047207T3 (en) 2025-12-03
EP3225243A1 (en) 2017-10-04
DK3225243T3 (da) 2025-09-29
EP2148683A1 (en) 2010-02-03
SI3225243T1 (sl) 2025-11-28
DK3335712T3 (da) 2025-10-20
EP3225243B1 (en) 2025-09-03
US20140274977A1 (en) 2014-09-18
FI3335712T3 (fi) 2025-10-23
EP2148683A4 (en) 2012-09-12
US20180021355A1 (en) 2018-01-25
JP2010525080A (ja) 2010-07-22
PT3335712T (pt) 2025-10-23
CA2683514A1 (en) 2008-11-06
WO2008134523A1 (en) 2008-11-06
JP2019196402A (ja) 2019-11-14
FI3225243T3 (fi) 2025-10-13
EP3335712B1 (en) 2025-09-10
CA2683514C (en) 2019-07-09
JP2017075183A (ja) 2017-04-20
US11801253B2 (en) 2023-10-31

Similar Documents

Publication Publication Date Title
ES3044311T3 (en) Method of safely and effectively treating and preventing secondary hyperparathyroidism in chronic kidney disease
ES2791535T3 (es) Terapia usando agente de repleción de la vitamina D y agente de reemplazo de la hormona de la vitamina D
ES2403107T3 (es) Método de tratamiento de insuficiencia y deficiencia de vitamina D
HK1259602B (en) Therapy using vitamin d repletion agent and vitamin d hormone replacement agent
HK1205936B (zh) 治疗维生素d不足和缺乏、继发性甲状旁腺功能亢进症和维生素d-响应疾病的方法和组合物
HK1193049A (en) Therapy using vitamin d repletion agent and vitamin d hormone replacement agent
HK1193049B (en) Therapy using vitamin d repletion agent and vitamin d hormone replacement agent